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Abstract
Introduction: The aim of the present study was to determine the brain areas associated with fibromyalgia, and 
whether pretreatment regional cerebral blood flow (rCBF) can predict response to gabapentin treatment.
Methods: A total of 29 women with fibromyalgia and 10 healthy women (without pain) matched for age were finally 
enrolled in the study. Technetium-99m ethyl cysteinate dimer single photon emission computed tomography (99mTc-
ECD SPECT) was performed in the fibromyalgia patients and controls. A voxel-by-voxel group analysis was performed 
using Statistic Parametric Mapping 5 (SPM5). After treatment with gabapentin, 16 patients were considered 
'responders', with decrease in pain of greater than 50% as evaluated by visual analogue scale (VAS). The remaining 13 
patients were considered 'poor responders'.
Results: We observed rCBF abnormalities, compared to control subjects, in fibromyalgia including hypoperfusion in 
the left culmen and hyperperfusion in the right precentral gyrus, right posterior cingulate, right superior occipital 
gyrus, right cuneus, left inferior parietal lobule, right middle temporal gyrus, left postcentral gyrus, and left superior 
parietal lobule. Compared to responders, poor responders exhibited hyperperfusion in the right middle temporal 
gyrus, left middle frontal gyrus, left superior frontal gyrus, right postcentral gyrus, right precuneus, right cingulate, left 
middle occipital gyrus, and left declive. The right middle temporal gyrus, left superior frontal gyrus, right precuneus, left 
middle occipital gyrus, and left declive exhibited high positive likelihood ratios.
Conclusions: The present study revealed brain regions with significant hyperperfusion associated with the default-
mode network, in addition to abnormalities in the sensory dimension of pain processing and affective-attentional 
areas in fibromyalgia patients. Furthermore, hyperperfusion in these areas was strongly predictive of poor response to 
gabapentin.
Introduction
Fibromyalgia (FM) is characterized by widespread mus-
culoskeletal chronic pain, fatigue, poor sleep, frequent
psychological difficulties, and multiple tender points
(TPs) on physical examination [1]. Although neither the
etiology nor the pathogenesis of this condition is fully
understood, FM appears to be a disorder of the central
nervous system (CNS) and a type of central sensitivity
syndrome [2]; thus, brain imaging studies of patients with
FM have been performed. Mountz and colleagues [3]
found hypoperfusion in the bilateral thalamus and bilat-
eral caudate nucleus using technetium-99m hexamethyl-
propylene amine oxime (99mTc-HMPAO) single-photon
emission computed tomography (SPECT). Kwiatek and
colleagues [4] also found hypoperfusion in the right thal-
amus and in a region near the right lentiform nucleus in
the caudate nucleus as well as inferior pontine tegmen-
tum using 99mTc-HMPAO SPECT. Guedj and colleagues
[5,6] found hyperperfusion in the somatosensory cortex
and hypoperfusion in the bilateral medial frontal, bilat-
eral anterior cingulate, bilateral posterior cingulate, and
cerebellar cortices using 99mTc-ethyl cysteinate dimer
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(ECD) SPECT. Thus, although several SPECT studies
revealed abnormal regional cerebral blood flow (rCBF) in
patients with FM, the findings have not been consistent
with each other.
Gabapentin is known to relieve neuropathic pain as
well as antidepressants in the treatment of FM [7].
Recently, the effectiveness of gabapentin was demon-
strated in a randomized, double-blind, placebo-con-
trolled clinical trial [7]. However, differences between
responders to gabapentin and non-responders were
unclear. The aim of the present study was to determine
the brain areas associated with FM using SPECT and
whether pretreatment rCBF can predict response to
gabapentin.
Materials and methods
Subjects
A total of 29 women with FM (45.1 ± 12.6 years of age,
range 22 to 67 years) who met the American College of
R h e u m a t o l o g y  c r i t e r i a  [ 1 ] ,  d i d  n o t  s u f f e r  f r o m  m a j o r
depression according to DSM-IV (Diagnostic and Statis-
tical Manual of Mental Disorders, Fourth Edition), and
visited the Juntendo University Hospital as outpatients
between July 2007 and April 2008 were enrolled in the
study. None of the patients had any other significant
medical illnesses such as stroke or malignancy with suspi-
cion of metastasis on computed tomography scan or
brain magnetic resonance imaging. Laboratory examina-
tion, including complete blood count, C-reactive protein,
rheumatoid factor, anti-nuclear antibody, C3 and C4 lev-
els, and anti-ds-DNA tests, were performed to exclude
any underlying disease. All patients were CNS drug-
naive. For comparison of imaging findings, 10 healthy
women without pain matched for age were also included
as a control group (44.5 ± 7.6 years). This study was
approved by the Ethics Committee of the Juntendo Uni-
versity School of Medicine. All subjects provided
informed consent in accordance with institutional guide-
lines.
Gabapentin therapy
Gabapentin was titrated in the following manner: 300
mg/day for the first week, 600 mg/day for the second
week, 1,200 mg/day for the third week, 1,800 mg/day for
the fourth week, and 2,400 mg/day for the fifth week. If a
patient could not tolerate 2,400 mg/day, the dosage was
reduced to a minimum of 1,200 mg/day. No additional
medication or new therapy was used during the course of
this study.
SPECT protocol and analysis
Patients were injected with 600 MBq of 99mTc-ECD. Radi-
onuclide angiography was performed immediately after
intravenous bolus injection of 3 mL of 99mTc-ECD. A
three-headed rotating gamma camera (Toshiba GCA-
9300A/DI; Toshiba Corporation, Tokyo, Japan) was used
for data acquisition, and a medical image processor
(GMS5500; Toshiba Corporation) was employed for
image processing. The energy window for acquisition was
set at 140 keV with a width of 20%. The gamma camera
was rotated continuously for 16 minutes, and SPECT data
were arranged into 90 projections over 360°.
Acquired images were reconstructed in a 128 × 128
matrix with a pixel size of 1.72 mm using a ramp filter
after being processed with a Butterworth filter (order 8,
0.13 to 0.15 cycles per pixel). Attenuation was corrected
using Chang's method (attenuation coefficient μ = 0.09
cm2/g). The projection data were reformatted to con-
struct transaxial images parallel to the orbitomeatal line.
The pixel size and slice thickness were 3.44 mm2 and 3.44
mm, respectively. A voxel-by-voxel group study was then
performed using Statistic Parametric Mapping 5 (SPM5)
(Welcome Department of Cognitive Neurology, Univer-
sity College, London, UK, running on MATLAB version
R2007a, The MathWorks, Inc., Natick, MA, USA).
Images were initially converted from ACR-NEMA1 to
analyze format using MRIcro and transferred to SPM5.
The data were then standardized with the Montreal Neu-
rological Institute (MNI) atlas using a 12-paramter affine
transformation, followed by non-linear transformations
and a trilinear interpolation. Dimensions of resulting vox-
els were 2 × 2 × 2 mm. Standardized data were smoothed
by a Gaussian filter (FWHM [full width at half maximum]
12 mm). The FM and control groups were compared
using the 'compare-populations one scan/subject' rou-
tine, which carries out a fixed-effects simple t test for
each voxel. Global normalization was performed using
proportional scaling. The SPM t maps were initially
obtained at a height threshold of P < 0.001, and then an
extent threshold of 50 voxels was applied to obtain a sta-
tistical threshold corrected for multiple comparisons for
the cluster (P < 0.05). MNI coordinates were finally con-
verted to Talairach coordinates using the Pick Atlas [8].
Using SPM5 the plot of adjusted normalized rCBF in the
voxel with the maximum value of each eligible cluster was
obtained, and the predictive values for discrimination of
the two subgroups of FM patients according to gabapen-
tin response were calculated. Normalized perfusion val-
ues of significant clusters were then extracted, and MNI
coordinates were finally converted to Talairach coordi-
nates using the Talairach Daemon database. The Mann-
Whitney U test was used to compare the adjusted nor-
malized rCBF subgroups of patients and controls. To
specify the relevance of visual analogue scale (VAS) pain
score, TP score, and duration of pain to rCBF, we per-Usui et al. Arthritis Research & Therapy 2010, 12:R64
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formed a multiple analysis, using VAS score, TP score,
and duration of pain as predictors, which tested the rela-
tionship between a predictor and an outcome (P < 0.05,
corrected for multiple comparison) in FM patients.
Pain assessment
Patients were considered responders when they exhibited
a decrease in VAS for pain of greater than 50% after treat-
ment. Other patients were considered poor responders.
Differences between the responder group and the poor
responder group in demography and clinical characteris-
tics were calculated with the unpaired t test. If data were
not sampled from Gaussian distributions, a non-para-
metric test (Mann-Whitney U test) was used. All statisti-
cal tests were two-tailed. Statistical significance was set at
P < 0.05.
Results
Patient disposition
During the study period, 35 patients with FM were regis-
tered, but due to adverse events, 6 patients discontinued
the study during the 12-week therapy phase. All 6
patients complained of headache and dizziness. A total of
29 patients with FM completed the therapy phase; 16 of
them were considered 'responders', whereas 13 of them
were considered 'poor responders'. In the responder
group, 11 of 16 patients could tolerate the full dose of
gabapentin (2,400 mg/day), whereas 5 patients could not:
among these 5 patients, 2 could tolerate 1,200 mg/day, 2
could tolerate 1,800 mg/day, and 1 could tolerate 2,100
mg/day. In the poor responder group, 9 of 11 patients
could tolerate the full dose, whereas 2 patients could not
(1,200 mg/day). There was no significant difference in the
proportion of patients who could tolerate the full dose of
gabapentin between the responder and poor responder
groups (69% versus 82%, P = 0.66).
Comparison of regional cerebral blood flow between the 
fibromyalgia and control groups
The FM patient group exhibited significant hypoperfu-
sion in the left culmen (Table 1 and Figure 1a, b) and
hyperperfusion in the right precentral gyrus, right poste-
rior cingulate, right superior occipital gyrus, right
cuneus, left inferior parietal lobule, right middle temporal
gyrus, left postcentral gyrus, and left superior parietal
lobule (Table 1 and Figure 1c, d). However, we found no
significant correlations between rCBF and cognitive indi-
cators of pain such as VAS score, TP score, and duration
of pain.
Comparison of regional cerebral blood flow among the 
responder, poor responder, and control groups
Demographic features and clinical features of the study
participants are shown in Table 2. The responder and
poor responder groups did not differ significantly in
mean age, pain duration, VAS for pain, or number of TPs.
Compared with the control group, the responder group
exhibited significant hypoperfusion in the right medial
frontal gyrus, left insula, left inferior frontal gyrus, and
left culmen in the cerebellum (Table 3 and Figure 2a, b) as
well as hyperperfusion in the left superior frontal gyrus
and the left postcentral gyrus (Table 3 and Figure 2c, d).
On the other hand, compared with the control group, the
poor responders exhibited significant hypoperfusion in
the left orbital gyrus (Table 4 and Figure 3a, b) and hyper-
perfusion in the right precentral gyrus, right posterior
cingulate, right precuneus, left middle frontal gyrus, right
superior temporal gyrus, left middle occipital gyrus, right
postcentral gyrus, and right inferior parietal lobule (Table
4 and Figure 3c, d).
Furthermore, compared with responders, poor
responders exhibited hyperperfusion in the right middle
t e m por a l gyrus, l eft  m iddle  fr o n ta l gyrus, l eft  s upe rio r
frontal gyrus, right postcentral gyrus, right precuneus,
right cingulate, left middle occipital gyrus, and left
declive in the cerebellum (Table 5 and Figure 4a, b). There
was no area with significant hypoperfusion in the poor
responder group compared with the responder group.
The sensitivity, specificity, positive predictive value, and
negative predictive value for prediction of poor response
to gabapentin are shown in Table 6. The following high
positive likelihood ratios (greater than 10) were observed:
right middle temporal gyrus, 13.6; left superior frontal
gyrus, 8 (specificity 100%); right precuneus, 8 (specificity
100%); left middle occipital gyrus, 12.4; and left declive,
12.4.
Discussion
Brain perfusion in fibromyalgia patients
In the present study, performed without noxious stimuli
in patients with FM, we found significant hyperperfusion
in the middle frontal gyrus, medial frontal gyrus, precu-
neus, cuneus, middle temporal gyrus, postcentral gyrus,
and inferior parietal lobule and significant hypoperfusion
in the culmen. Although several SPECT studies revealed
abnormal rCBF in patients with FM, the findings were
inconsistent, as noted in the Introduction, and also dif-
fered from those of the present study. Differences in
experimental conditions could explain these discrepan-
cies in findings. First, Mountz and colleagues [3] and
Kwiatek and colleagues [4] used 99mTc-HMPAO rather
than 99mTc-ECD as a tracer. Although uptakes of 99mTc-
ECD and 99mTc-HMPAO in the brain exhibit a fixed dis-
tribution, these tracers have different pharmacokinetics
and yield different image qualities. 99mTc-ECD uptake is
known to reflect cerebral blood flow more closely than
99mTc-HMPAO and to be more sensitive in estimatingUsui et al. Arthritis Research & Therapy 2010, 12:R64
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Figure 1 Comparison of regional cerebral blood flow (rCBF) between patients with fibromyalgia (FM) and age-matched healthy controls. 
Maximum intensity projections of Statistic Parametric Mapping 2 (SPM2) results from comparison of rCBF between patients with FM and age-matched 
healthy controls are shown. The FM patient group exhibited (a, b) significant hypoperfusion in the left culmen and (c, d) significant hyperperfusion 
in the right precentral gyrus, right posterior cingulate, right superior occipital gyrus, right cuneus, left inferior parietal lobule, right middle temporal 
gyrus, left postcentral gyrus, and left superior parietal lobule. Height threshold is less than 0.001, corrected for multiple comparison.
Table 1: Regions of significant hyperperfusion and hypoperfusion in the fibromyalgia group
κ Z score x, mm y, mm z, mm Localization
Hyperperfusion 134 4.55 66 -10 30 Right precentral 
gyrus
262 4.16 2 -62 14 Right posterior 
cingulate
824 3.98 36 -82 32 Right superior 
occipital gyrus
429 3.95 18 -96 -6 Right cuneus
220 3.57 50 -38 52 Left inferior parietal 
lobule
55 3.54 52 -46 6 Right middle 
temporal gyrus
113 3.52 -30 -42 68 Left postcentral 
gyrus
3.74 -14 -74 56 Left superior parietal 
lobule
709 4.66 -2 56 -22 Left superior frontal 
gyrus
Hypoperfusion 1,111 4.38 -12 -32 -18 Left culmen
Results are listed by clusters. K value, Z score, Talairach coordinates of peak voxel, and anatomic localization are provided for each cluster.Usui et al. Arthritis Research & Therapy 2010, 12:R64
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regional metabolic rate, especially in the medial temporal
lobe of the cortex. Second, although Guedj and col-
leagues [5] used 99mTc-ECD (as in the present study),
their subjects' characteristics differed from ours. Subjects
in the study of Guedj and colleagues were hospitalized
because of treatment failure, whereas our subjects were
CNS drug-naive outpatients without major depressive
disorder. Our findings were therefore not affected by
CNS drugs. In contrast, subjects in the study of Guedj
and colleagues may have been affected by administered
CNS drugs since their hospitalization was due to treat-
ment failure. Our findings for FM patients without previ-
ous use of CNS drugs may have reflected primary
changes in rCBF in FM.
Interestingly, the regions of hyperperfusion observed in
the present study have been previously referred to as the
'default mode network' (DMN) [9,10]. Previous func-
tional magnetic resonance imaging (fMRI) studies
showed that DMN exhibited decreased neural activity
during goal-related tasks compared with that at rest
[11,12] and that it appears to be involved in various
aspects of self-referential processing [13], which in con-
certed action maintain the brain resting state [14]. In
other words, in the normal brain, the DMN provides 'a
balance of opposing forces' to enhance 'the maintenance
of information for interpreting, responding to, and even
predicting environmental demands' ([12]. Although the
mechanism by which it does so is unclear, pain is known
Figure 2 Comparison of regional cerebral blood flow (rCBF) between the responder group and age-matched healthy controls. Maximum 
intensity projections of Statistic Parametric Mapping 2 (SPM2) results from comparison of rCBF between the responder and age-matched healthy con-
trols are shown. The responder group exhibited (a, b) significant hypoperfusion in the right medial frontal gyrus, left insula, left inferior frontal gyrus, 
and left culmen in the cerebellum and (c, d) significant hyperperfusion in the left superior frontal gyrus and the left postcentral gyrus. Height threshold 
is less than 0.001, corrected for multiple comparison.Usui et al. Arthritis Research & Therapy 2010, 12:R64
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Table 2: Demographic and clinical features of the responder and poor responder groups
Responders Poor responders
Number 16 13
Age, years 45.3 ± 9.1 39.5 ± 12.6
Duration of illness, years 3.0 ± 1.9 3.2 ± 2.4
Tender points, 0 to 18 13.9 ± 2.0 15.4 ± 2.8
VAS at baseline, 0 to 100 81.3 ± 9.6 86.9 ± 11.8
VAS after gabapentin, 0 to 100 15.6 ± 7.3 83.1 ± 16.0
Dose of gabapentin, milligrams 2,156.3 ± 427.4 2,215.4 ± 450.6
VAS, visual analogue scale.
Figure 3 Comparison of regional cerebral blood flow (rCBF) between the poor responder group and age-matched healthy controls. Maxi-
mum intensity projections of Statistic Parametric Mapping 2 (SPM2) results from comparison of rCBF between the poor responder and age-matched 
healthy controls are shown. The poor responder group exhibited (a, b) significant hypoperfusion the left orbital gyrus and (c, d) significant hyperper-
fusion in the right precentral gyrus, right posterior cingulate, right precuneus, left middle frontal gyrus, right superior temporal gyrus, left middle oc-
cipital gyrus, right postcentral gyrus, and right inferior parietal lobule. Height threshold is less than 0.001, corrected for multiple comparison.Usui et al. Arthritis Research & Therapy 2010, 12:R64
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to interact with the DMN. Acute pain [15] is known to
induce deactivation in DMN regions, whereas chronic
pain may be associated with disruption of the DMN [16].
Furthermore, perception of somatosensory stimuli near
sensory threshold is facilitated by decreased DMN activ-
ity in a brief pre-event resting period [9]. Also, in patients
with FM, continuous perception of pain may alter the
brain resting state. Since our findings did not include
connectivity data, we are unable to address the question
of the relationship between the pathophysiology of FM
and DMN. However, the present study yielded the first
observation of hyperperfusion in DMN regions in
patients with FM.
Differences in brain perfusion between responders to 
gabapentin and non-responders among fibromyalgia 
patients
Gabapentin is thought to exert antinociceptive effects
primarily by modulation of calcium channels via α2δ
binding, which reduces the release of several neurotrans-
mitters involved in pain processing, such as glutamate,
noradrenaline, and substance P [17]. However, the mech-
anism of action of gabapentin in the human brain has yet
to be elucidated. In this study, pronounced pretreatment
hyperperfusion in the right middle temporal gyrus, left
superior frontal gyrus, right precuneus, left middle occip-
ital gyrus, and left declive appeared to be predictive of
Table 4: Regions of significant hyperperfusion and hypoperfusion in the poor responder group
κ Z score x, mm y, mm z, mm Localization
Hyperperfusion 253 4.87 66 -10 34 Left precentral 
gyrus
758 4.55 2 -62 14 Right posterior 
cingulate
3,168 4.16 40 -76 34 Right precuneus
710 3.98 -20 -8 66 Left middle 
frontal gyrus
1,052 3.95 54 -48 8 Right superior 
temporal gyrus
820 3.57 -38 -88 -2 Right middle 
occipital gyrus
201 3.52 10 -36 82 Left postcentral 
gyrus
134 3.54 48 -42 58 Left inferior 
parietal lobule
Hypoperfusion 207 4.38 -14 36 -26 Left orbital gyrus
Results are listed by clusters. κ value, Z score, Talairach coordinates of peak voxel, and anatomic localization are provided for each cluster.
Table 3: Regions of significant hyperperfusion and hypoperfusion in the responder group
κ Z score x, mm y, mm z, mm Localization
Hyperperfusion 419 4.82 -24 -4 68 Left superior 
frontal gyrus
169 3.80 -30 -42 68 Left postcentral 
gyrus
Hypoperfusion 420 4.23 2 60 -16 Right medial 
frontal gyrus
2,053 4.66 -44 -4 10 Left insula
420 4.23 -18 30 -24 Left inferior 
frontal gyrus
258 4.38 -14 -32 -14 Left culmen
Results are listed by clusters. κ value, Z score, Talairach coordinates of peak voxel, and anatomic localization are provided for each cluster.Usui et al. Arthritis Research & Therapy 2010, 12:R64
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poor response to gabapentin given the high positive like-
lihood ratios obtained for these regions. These findings
are not consistent with a previous finding for non-
responders to ketamine, in which hypoperfusion in the
medial frontal area was observed [18]. As noted above,
subjects in the study of Guedj and colleagues were hospi-
talized because of treatment failure whereas our subjects
were CNS drug-naive outpatients without major depres-
sive disorder, and our findings were correspondingly not
affected by CNS drugs. In contrast, subjects in the study
of Guedj and colleagues may have been affected by previ-
ously given CNS drugs because their hospitalization was
due to treatment failure. Interestingly, areas predictive of
poor response to gabapentin are involved in the DMN. It
Figure 4 Comparison of regional cerebral blood flow (rCBF) between the responder group and the poor responder group. Maximum inten-
sity projections of Statistic Parametric Mapping 2 (SPM2) results from comparison of rCBF between the responder and poor responder groups are 
shown. (a, b) The poor responder group exhibited hyperperfusion in the right middle temporal gyrus, left middle frontal gyrus, left superior frontal 
gyrus, right postcentral gyrus, right precuneus, right cingulate, left middle occipital lobule, and left declive. Height threshold is less than 0.001, cor-
rected for multiple comparison.Usui et al. Arthritis Research & Therapy 2010, 12:R64
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thus appears possible that FM, especially intractable FM
with gabapentin, is related to DMN functioning.
Several limitations of this study should be considered.
First, as we have no post-treatment SPECT data, further
work will be needed to clarify the potential reversibility of
our findings after treatment. Second, this was an open
study with a flexible dose design, which limited assess-
ment of the effectiveness of gabapentin. Third, because
the trial was only 12 weeks in duration, its results may not
be generalizable to longer treatment periods, and the
long-term efficacy of gabapentin should be explored in
future clinical trials. Fourth, the results of this trial may
not be generalizable to patients with certain comorbid
psychiatric disorders or patients with comorbid rheuma-
tologic or other medical disorders since patients with
these conditions were excluded from the trial. Finally,
other brain imaging studies, such as positron emission
t o m o g r a p h y  a n d  f M R I ,  w i l l  b e  n e e d e d  t o  c l a r i f y  t h e
pathophysiology of FM and the characteristics of
responders to gabapentin treatment.
Conclusions
The present study showed significant hyperperfusion in
areas associated with the DMN in addition to abnormali-
ties in the sensory dimension of pain processing and
affective-attentional areas in patients with FM. Further-
more, hyperperfusion in these areas was highly predictive
of poor response to gabapentin. Further studies yielding
Table 6: Sensitivity, specificity, and positive and negative predictive values based on pretreatment regional cerebral 
blood flow of each cluster
Localization Sensitivity, % Specificity, % PPV, % NPV, %
Right middle temporal 
gyrus
84.6 93.8 91.7 88.2
Left middle frontal 
gyrus
84.6 81.3 78.6 86.7
Left superior frontal 
gyrus
69.2 100 100 80
Right postcentral 
gyrus
84.6 68.8 68.8 84.6
Right precuneus 76.9 100 100 84.2
R i g h t  c i n g u l a t e 7 6 . 98 1 . 37 6 . 98 1 . 3
Left middle occipital 
lobule
76.9 93.8 90.9 83.3
L e f t  d e c l i v e 7 6 . 99 3 . 89 0 . 98 3 . 3
NPV, negative predictive value; PPV, positive predictive value.
Table 5: Regions of significant hyperperfusion in the poor responder group compared with the responder group
κ Z score x, mm y, mm z, mm Localization
Hyperperfusion 1,260 4.08 42 -62 16 Right middle 
temporal gyrus
95 3.88 -46 6 50 Left middle 
frontal gyrus
95 3.88 -20 38 52 Left superior 
frontal gyrus
69 3.67 56 -12 56 Right postcentral 
gyrus
578 3.67 14 -76 28 Right precuneus
59 3.58 4 20 36 Right cingulate
70 3.54 -20 -80 4 Left middle 
occipital lobule
77 3.51 -20 -80 -26 Left declive
Results are listed by clusters. κ value, Z score, Talairach coordinates of peak voxel, and anatomic localization are provided for each cluster.Usui et al. Arthritis Research & Therapy 2010, 12:R64
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fMRI and connectivity data will be needed to clarify the
association between pathogenesis of FM and DMN.
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